NASDAQ:CRDF

Cardiff Oncology Q3 2026 Earnings Results & Report

Cardiff Oncology logo
$0.85 0.00 (-0.15%)
Closing price 04:00 PM Eastern
Extended Trading
$0.83 -0.02 (-2.41%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardiff Oncology beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.12 versus the -$0.1380 consensus estimate, while revenue of $171 thousand topped the $81 thousand estimate by $90.00 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
7:00 AM ET

Cardiff Oncology EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.1380
Beat/Miss
Beat by +$0.0180
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Cardiff Oncology Revenue Results

Actual Revenue
$171 thousand
Expected Revenue
$81 thousand
Beat/Miss
Beat by +$90.00 thousand
YoY Revenue Growth
N/A

Cardiff Oncology Q3 2026 Earnings FAQ

Cardiff Oncology (NASDAQ:CRDF) reported earnings of -$0.12 per share for Q3 2026, beating the consensus estimate of -$0.1380. The report was announced on Thursday, November 12, 2026.

Cardiff Oncology reported revenue of $171 thousand for Q3 2026, against a consensus estimate of $81 thousand.

Cardiff Oncology Earnings Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
Cardiff: FDA Grants Fast Track Designation To Onvansertib
See More Cardiff Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiff Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiff Oncology and other key companies, straight to your email.

About Cardiff Oncology

Cardiff Oncology (NASDAQ:CRDF) is a clinical-stage biotechnology company focused on developing cancer treatments. Its lead drug candidate, onvansertib, is an oral, selective inhibitor of polo-like kinase 1 (PLK1), a protein involved in cell division that the company is investigating as a target in cancer therapy.

The company is studying onvansertib in combination with existing treatments for several cancers, including metastatic colorectal cancer and acute myeloid leukemia. These programs remain in clinical development, and the candidate is not an approved treatment.

Based in San Diego, California, Cardiff Oncology was formerly known as Trovagene, Inc. The company adopted its current name in 2020. Mark Erlander serves as its chief executive officer.

View Cardiff Oncology Profile